COMBINATION OF A NUCLEOSIDE INHIBITOR OF POLYMERASE AND A MACROCYCLIC INHIBITOR OF PROTEASE AND ITS APPLICATION FOR TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND DISTURBED HEPATIC FUNCTION

摘要

1. A composition comprising a first compound or a pharmaceutically acceptable salt thereof, wherein the first compound is a second compound or a pharmaceutically acceptable salt thereof, wherein the second compound is 2. A composition consisting essentially of the first compound or a pharmaceutically acceptable salt thereof, wherein the first compound is a second compound or a pharmaceutically acceptable salt thereof, wherein the second compound is 3. A composition according to claim 1 or 2, further comprising a pharmaceutically acceptable excipient, diluent or carrier. The composition of claim 1 or 2, wherein the composition comprises the first compound or a pharmaceutically acceptable salt thereof in an amount of from about 9000 to about 50 mg, or in an amount of from about 5000 to about 150 mg, or in an amount of from about 2000 to about 300 mg, or in an amount from about 1000 to about 450 mg, or in an amount of from about 1000 to about 500 mg. 5. The composition of claim 1 or 2, wherein the composition comprises a second compound or a pharmaceutically acceptable salt thereof in an amount of from about 2000 to about 2 mg, or in an amount of from about 1600 to about 25 mg, or in an amount of from about 500 to about 50 mg, or in an amount of about 200 to about 100 mg. 6. The composition according to claim 1 or 2, where the composition contains the first compound or its pharmaceutically acceptable salt in a total amount of from about 1 to about 99 wt.%, Or from about 5 to about 90 wt.%, Or from about 10 to about 80 wt. wt.%, from about 20 to about 70 wt.%, or from about 30 to about 60 wt.%, or from about 40 to about 50 wt.%, in terms of the total amount of the first compound